PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trial

@article{Chapal2015PREventingDG,
  title={PREventing Delayed Graft Function by Driving Immunosuppressive InduCtion Treatment (PREDICT-DGF): study protocol for a randomized controlled trial},
  author={M. Chapal and Y. Foucher and Monique Marguerite and K. Neau and E. Papuchon and P. Daguin and E. Morelon and G. Mourad and {\'E}. Cassuto and M. Ladri{\`e}re and C. Legendre and M. Giral},
  journal={Trials},
  year={2015},
  volume={16}
}
BackgroundIn kidney transplantation, the use of Anti-Thymocyte Globulins (ATG) as induction therapy has been described as a possible treatment for reducing the prevalence of Delayed Graft Function (DGF). ATG possesses pharmaceutical proprieties that could help control the lesions caused by ischemia reperfusion injury. However, other studies have questioned this potential protective effect. We hypothesized that the benefits related to ATG for reducing DGF prevalence may be higher and more… Expand
8 Citations
Delayed graft function and its management in children
  • 10
Utility and safety of early allograft biopsy in adult deceased donor kidney transplant recipients
  • 5

References

SHOWING 1-10 OF 25 REFERENCES
Prediction of delayed graft function after renal transplantation.
  • 31
Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
  • 561
  • PDF
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
  • 153
  • PDF
...
1
2
3
...